Weight Drugs Cut Addiction, Overdose Risks

New research suggests that GLP-1 receptor agonists, widely recognized for treating type 2 diabetes and obesity, might also play a role in managing addiction and reducing overdose risks. A significant US study analyzed data from 606,434 US veterans over three years.

The findings indicate that GLP-1s reduced the risk of alcohol-related disorders by 18%, cannabis use by 14%, cocaine use by 20%, nicotine use by 20%, and opioid use by 25% compared to other diabetes drugs. Crucially, for individuals already using substances, these medications were linked to a 39% lower risk of overdosing, a 31% lower risk of requiring emergency care, and a 50% lower risk of mortality.

Experts emphasize that while these observational findings are promising, they do not prove that GLP-1s prevent or treat addiction. Further clinical trials are necessary to establish a direct causal link. The study also highlighted that weight regain is a significant issue, with individuals typically regaining about 60% of lost weight within a year of stopping the medication.

Concerns regarding side effects like nausea and high costs contribute to many users discontinuing GLP-1s within two years. Additionally, a survey revealed that a substantial number of users hide their medication use due to fear of judgment, with many facing accusations of taking an "easy way out."